The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine — the nation's only traditional ...

Shares of Novavax Inc. NVAX slipped 3.90% to $6.41 Thursday, on what proved to be an all-around great trading session for the ...

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...

Novavax Inc. closed 72.05% short of its 52-week high of $23.86, which the company reached on June 6th.

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 ...

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Novavax shows financial improvement but faces vaccine challenges. Read why I rated NVAX stock as 'Hold' and what risks and ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

DEFINITION OF ELDERLY IS THEY’RE SAYING 65 AND OLDER. The U.S. Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a ...